Weight-Loss Drugs Are Splitting Health Care Into Coverage and Cash
As employers retreat from GLP-1 coverage, telehealth platforms are becoming the backup market. Reuters reporter Amina Niasse reported on June 25 that Hims & Hers Health may benefit as employers begin dropping coverage of weight-loss drugs such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound and Foundayo in 2027. The shift is being driven by…